Valeant Pharmaceuticals International, Inc.
9.25 -0.13(-1.39%) Date:
Valeant’s upcoming results are unlikely to reflect its strength in core businesses, according to Wells Fargo analyst
While Dermatology NRx remained flat Wow, they fell 42.1% YoY on 4-week rolling basis, according to RBC Capital analyst
While Valeant's 1Q set-up appears reasonable, its long-term outlook remains shaky, according to JPMorgan analyst
Siliq is unlikely to change Valeant’s dermatology unit fortunes going forward, according to Piper Jaffray analyst
Valeant investors advised to remain cautious ahead given the drugmaker's ongoing circumstances